These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21699366)

  • 1. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
    Hay JW; Zhou ZY
    J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
    Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
    Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
    Hay JW; Chaugule SC; Young G
    Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Adv Ther; 2009 Jan; 26(1):68-88. PubMed ID: 19156372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
    Zhou ZY; Hay JW
    Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
    Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
    Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K; Astermark J; Donfield S; Berntorp E
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
    Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2010 Mar; 16(2):366-8; discussion 369-71. PubMed ID: 19811544
    [No Abstract]   [Full Text] [Related]  

  • 20. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
    Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
    Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.